Article

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance

2026-03-12

Abstract excerpt

Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide clinical benefits, the development of resistance limits durable response. Transcriptomic and proteomic analyses reveal that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell cycle progression....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9a636886-0910-543e-a0f3-9e8a4d3b9f68
DOI: 10.64898/2026.03.10.710937

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor ResistanceDOI 10.64898/2026.03.10.710937Read

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.Semantic proximity Read

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic CancerSemantic proximity Read

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.Semantic proximity Read

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalSemantic proximity Read

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.Semantic proximity Read

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.Semantic proximity Read

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease modelsSemantic proximity Read

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Semantic proximity Read

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read